Jincheng Pharmaceutical (300233): High upstream costs are falling, gross margin is improving month-on-month, waiting for new products to open up room for growth
Jincheng Pharmaceutical (300233) In-depth Report: Relying on the “Double Synthesis Technology Platform”, various products are expected to be released in the future
Jincheng Pharmaceutical (300233): Semi-annual report results are impressive, synthetic biology research results have been implemented one after another
Jincheng Pharmaceutical (300233): Dual platforms drive revenue growth of 43%, and key projects advance smoothly
Jincheng Pharmaceutical (300233): Performance meets expectations The third quarter is the starting point for a new round of medium- to long-term growth
Jincheng Pharmaceutical (300233): Pharmaceutical and chemical platforms are steadily developing synthetic biology platforms to welcome new opportunities
Jincheng Pharmaceutical (300233) In-depth Report: Biosynthesis and Chemical Synthesis Dual Platform Energy Begins to Explode
Jincheng Pharmaceutical (300233): Encouraging implementation of synthetic biology, CDMO leading the company's new development
Jincheng Pharmaceutical (300233): Nicotine production license obtained, industry leaders took advantage of the wind
Jincheng Pharmaceutical (300233): Cephalosporin & Glutathione Duo Entering the New Blue Ocean of Nicotine
Jincheng Pharmaceutical (300233): Winning the domestic procurement bid is only the first step at a major inflection point in the company's development
Jincheng Pharmaceutical (300233): Innovative drug investment cooperation has made breakthrough progress
Jincheng Pharmaceutical (300233): 700 million in goodwill finally be reduced in value, lightweight, and will set sail again in 2021!
Jincheng Pharmaceutical (300233): The three major lightweight sectors will all usher in three years of high growth
金城医药(300233)季报点评:20Q3渠道端继续发力 销售回款高增长
金城医药(300233):注射用亚胺培南西司他丁钠获进口注册
金城医药(300233)半年报点评:医药工业及生物制药成长稳健 制剂业务疫情期间蓄力待发
金城医药(300233):业绩虽下滑 核心业务保持增长不易
金城医药(300233):头孢侧链中间体和谷胱甘肽龙头 注射剂集采潜在受益者
金城医药(300233)公司深度研究:头孢&谷胱甘肽双料龙头 集团作战布局亿级蓝海市场